Q1 EPS Forecast for Precision BioSciences Boosted by Analyst

Precision BioSciences, Inc. (NASDAQ:DTIL) – Research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Precision BioSciences in a research report issued to clients and investors on Thursday, March 19th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.27) per share for the quarter, up from their previous forecast of ($0.82). The consensus estimate for Precision BioSciences’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.43) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($2.21) EPS.

Several other research firms have also weighed in on DTIL. Jefferies Financial Group reaffirmed a “buy” rating and issued a $19.00 target price on shares of Precision BioSciences in a report on Friday, March 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Precision BioSciences currently has a consensus rating of “Hold” and a consensus target price of $39.50.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $6.52 on Monday. The stock has a market cap of $161.24 million, a PE ratio of -1.27 and a beta of 1.28. The business has a fifty day moving average of $4.48 and a two-hundred day moving average of $5.06. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $8.82. The company has a debt-to-equity ratio of 0.24, a quick ratio of 13.32 and a current ratio of 13.32.

Institutional Investors Weigh In On Precision BioSciences

A number of hedge funds have recently added to or reduced their stakes in DTIL. HBK Sorce Advisory LLC acquired a new stake in Precision BioSciences in the 4th quarter valued at about $38,000. Engineers Gate Manager LP acquired a new position in shares of Precision BioSciences during the fourth quarter worth approximately $43,000. Occudo Quantitative Strategies LP bought a new stake in shares of Precision BioSciences during the fourth quarter valued at approximately $52,000. Miller Financial Services LLC grew its stake in shares of Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Precision BioSciences in the third quarter valued at approximately $72,000. Institutional investors own 37.99% of the company’s stock.

Insiders Place Their Bets

In other news, insider J. Jefferson Smith sold 10,200 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $4.03, for a total value of $41,106.00. Following the completion of the sale, the insider directly owned 110,184 shares in the company, valued at approximately $444,041.52. This trade represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO John Alexander Kelly sold 15,213 shares of Precision BioSciences stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total value of $61,308.39. Following the completion of the transaction, the chief financial officer directly owned 106,448 shares of the company’s stock, valued at $428,985.44. This represents a 12.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 93,845 shares of company stock valued at $376,677. 4.00% of the stock is currently owned by corporate insiders.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.